100 -6 (92) 2026 - Reymnazarova G.Dj. - ADVANCING THE DIFFERENTIAL DIAGNOSIS OF HSIL AND LSIL IN PERIMENOPAUSE: A REVIEW OF MODERN OBJECTIVE CRITERIA

ADVANCING THE DIFFERENTIAL DIAGNOSIS OF HSIL AND LSIL IN PERIMENOPAUSE: A REVIEW OF MODERN OBJECTIVE CRITERIA

Reymnazarova G.Dj. - Tashkent State Medical University

Resume

Cervical cancer remains a significant global health burden, ranking as the fourth most common malignancy among women worldwide, with approximately 660,000 new cases and 350,000 deaths reported in 2022. Despite advances in vaccination and screening, the disease disproportionately affects low- and middle-income countries, where incidence and mortality rates remain alarmingly high. Persistent infection with high-risk human papillomavirus (HPV) types, predominantly HPV 16 and 18, drives cervical carcinogenesis through the oncogenic actions of E6 and E7 proteins, which inactivate tumor suppressors p53 and pRb. We examine the diagnostic utility of dual p16/Ki-67 immunostaining as a triage strategy for HPV-positive women, highlighting its superior sensitivity and specificity compared to conventional cytology. Emerging technologies including atomic force microscopy, scanning electron microscopy, and elemental tissue analysis are discussed as complementary tools for characterizing the biophysical and biochemical landscape of cervical dysplasia. The review further considers the role of DNA methylation markers, artificial intelligence-assisted diagnostics, and the incorporation of these modalities into risk stratification algorithms. Special attention is devoted to the clinical implications of these innovations for women in the premenopausal age group, where early detection and individualized management are critical for cancer prevention and fertility preservation.

Key words: differential diagnosis of HSIL and LSIL in perimenopause, cervical cancer, vaccination, screening, human papillomavirus, cancer prevention and fertility preservation.

First page

602

Last page

609

For citation:Reymnazarova G.Dj. - ADVANCING THE DIFFERENTIAL DIAGNOSIS OF HSIL AND LSIL IN PERIMENOPAUSE: A REVIEW OF MODERN OBJECTIVE CRITERIA//New Day in Medicine 6(92)2026 602-609 https://newdayworldmedicine.com/en/article/7699

List of References

1. Tillyashaykhov MN, et al. Cervical cancer epidemiology in Uzbekistan. Tashkent; 2017.
2. Zhou Q, Li T, Zhu L, et al. Clinical performance of cervical cancer screening strategies in premenopausal and postmenopausal women. Menopause. 2025;32(5):456-465.
3. Rosendo-Chalma P, Antonio-Vejar V, Ortiz Tejedor JG, et al. The hallmarks of cervical cancer: molecular mechanisms induced by HPV. Biology (Basel). 2024;13(2):77. doi:10.3390/biology13020077.
4. Hamidi Sofiani V, Veisi P, Rezaei Zadeh Rukerd M, et al. The complexity of HPV in cancers: a narrative review. Infect Agents Cancer. 2023;18:13. doi:10.1186/s13027-023-00491-5.
5. Santoro A, Inzani F, Angelico G, et al. Recent advances in cervical cancer management: prognostic factors. Cancers (Basel). 2023;15(4):1137. doi:10.3390/cancers15041137.
6. Tung HJ, Schwarzschild G, Gopep NS, et al. Cervical cancer screening after menopause. Healthcare (Basel). 2025;13(10):1157.
7. Fitch KC, Bohn JA, Emerson J, et al. Acceptability of HPV self-collection and telehealth. Gynecol Oncol Rep. 2023;48:101226. doi:10.1016/j.gore.2023.101226.
8. Trzeszcz M, Mazurec M, Jach R, et al. p16/Ki67 dual stain triage in primary HPV screening. J Med Virol. 2023;95(11):e29271. doi:10.1002/jmv.29271.
9. Liu Y, Yang S, Ma Y, et al. HPV E6/E7 mRNA screening in premenopausal women. Int J Gynaecol Obstet. 2024;167(2):345-354.
10. Huang Y, Feng L, Huang J, et al. E6/E7 mRNA, P16, Ki-67 for CIN2+/CIN3+. J Med Virol. 2025;97(5):e70405.

    file

    download